

## Comparison of the efficacy and safety of oligomeric proanthocyanidins and nifedipine in patients with primary Raynaud's phenomenon: An open-label, randomized, prospective pilot study

Kyung-ann Lee , Seung-hwan Jung , Jong-sun Kim , Hyun-sook Kim 

Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea

Raynaud's phenomenon (RP) is reversible vasospasm of peripheral arteries caused by cold temperatures or emotional stress.<sup>1</sup> Oligomeric proanthocyanidins, a major component of

Entelon<sup>®</sup>, a potent antioxidant and anti-inflammatory agent, reduce vascular permeability and improve capillary strength, vascular function, and peripheral circulation in the treatment of

**Table 1.** Demographic and baseline characteristics of the study population

	Entelon <sup>®</sup> (n=9)				Nifedipine (n=9)				p
	n	%	Median	IQR	n	%	Median	IQR	
Age (year)			51.00	17			52.00	22	0.931
Sex									
Female	7	77.8			5	55.56			0.620
Body mass index (kg/m <sup>2</sup> )			22.00	5.8			22.90	2.75	0.796
Smoking	0	0			1	11.1			1.000
Raynaud phenomenon									
Disease duration (months)			48.0	144			60.0	96	0.931
Attack frequency (times/day)			5.0	6			4.0	4	0.535
Attack duration (min)			15.0	55.2			10.0	12.0	0.297
Raynaud condition score			5.5	2.5			6.0	2.3	0.796
Medication use (n, %)									
Steroid	0	0			0	0			
Calcium channel blockers	0	0			0	0			
ACEi/ARB	0	0			0	0			
Aspirin	0	0			0	0			
Oral contraceptive	1	11.1			0	0			
Statin	1	11.1			0	0			

IQR: Interquartile range; ACEi: Angiotensin converting enzyme inhibitors; ARB: Angiotensin II receptor blocker.

**Received:** September 21, 2021 **Accepted:** September 22, 2022 **Published online:** November 04, 2022

**Correspondence:** Hyun-sook Kim, MD. Division of Rheumatology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, 59, Daesagwan-ro, Yongsan-gu, 04401 Seoul, Republic of Korea. E-mail: healthyra@schmc.ac.kr

### Citation:

Lee KA, Jung SH, Kim JS, Kim HS. Comparison of the efficacy and safety of oligomeric proanthocyanidins and nifedipine in patients with primary Raynaud's phenomenon: An open-label, randomized, prospective pilot study. Arch Rheumatol 2023;38(3):477-479.

©2023 Turkish League Against Rheumatism. All rights reserved.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes (<http://creativecommons.org/licenses/by-nc/4.0/>).

**Table 2.** Changes in clinical outcomes of RP before and after treatment with Entelon® and nifedipine

	Entelon® (n=9)				Nifedipine (n=9)				Change score						
	Baseline		2 weeks		Baseline		2 weeks		Entelon®		Nifedipine		p		
	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR			
Attack frequency (times/day)	5.0	6.0	1.0	5.25	0.008	4.0	3.5	4.75	0.007	-2.5	4.0	-0.5	2.25	0.063	
Attack duration (min)	15.0	55.2	11.07	29.04	0.008	10.0	12.0	12.68	0.011	-3.93	30.81	-3.25	6.48	0.402	
Raynaud condition score	5.5	2.5	4.0	2.0	0.007	6.0	2.3	4.25	0.007	-1.5	2.25	-2.0	4.0	0.893	
	Entelon® (n=6)				Nifedipine (n=8)				Change score						
	Baseline		6 weeks		Baseline		6 weeks		Entelon®		Nifedipine		p		
	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR	Median	IQR			
Attack frequency (times/day)	5.5	6.7	1.5	4.81	0.027	4.5	3.75	2.5	4.69	0.012	-3.0	4.19	-1.37	1.88	0.081
Attack duration (min)	17.5	82.05	12	51.53	0.249	8.0	13.4	4.6	7.98	0.017	-2.85	79.9	-2.7	1.000	
Raynaud condition score	5.5	3.25	4	5.13	0.074	6.0	2.4	2.3	4.9	0.012	-2.5	4.9	-2.5	3.4	0.897

RP: Raynaud's phenomenon; IQR: Interquartile range.

venous insufficiency and non-proliferative diabetic retinopathy.<sup>2-4</sup> Previous studies have suggested that the levels of reactive oxygen species increase, and those of antioxidant ascorbic acid decrease, in patients with primary RP.<sup>5</sup> These findings support the notion that oxidative stress has a role in primary RP. This open-label, randomized, prospective pilot study assessed the safety and efficacy of Entelon® compared to nifedipine in patients with primary RP.

Between January and June 2018, we recruited adult patients with primary RP according to the international consensus criteria for the diagnosis of RP who had at least three attacks of RP a week, described as color change and paresthesias.<sup>6</sup> We excluded patients with secondary RP, severe cardiopulmonary and renal disorder, epilepsy, edema from causes such as diabetes, chronic inflammatory disease, hypothyroidism, liver diseases, anemia and malnutrition.

The patients were randomized into experimental (Entelon® 150 mg twice a day) and control (nifedipine 30 mg once daily) groups in an open-label trial. The patients recorded a daily RP attack diary regarding the number of RP attacks and the duration of each RP attack. They also completed the Raynaud's Condition Score (RCS) which is a daily self-assessment of RP activity (0-10 scale).<sup>7</sup> As primary endpoints, RCS, frequency and duration of RP attack were evaluated after six weeks of treatment. Adverse events (AEs) within the study period of six weeks, changes in patterns of nailfold capillaroscopy (NFC) baseline and six weeks of treatment were also assessed. Changes from baseline after two and six weeks were compared using the Wilcoxon signed-rank test. A *p* value of <0.05 was considered statistically significant.

In total, 18 patients were enrolled with nine in each group. Table 1 shows the demographic characteristics of the study population. After two-week treatment, both nifedipine and Entelon® groups showed a significant improvement of RP clinical outcomes. After six-week treatment of nifedipine, the duration and frequency of RP attack significantly decreased (*p*=0.012, and *p*=0.017, respectively) and RCS improved (*p*=0.012). In the Entelon® group, the RP frequency significantly decreased (*p*=0.027) after six weeks of treatment (Table 2). No significant

differences in the absolute changes of duration and frequency of RP, and RCS per time point between two groups was observed. No unexpected AEs were noted, and one patient in the Entelon® group experienced diarrhea. Abnormal NFC pattern was not observed at baseline and six weeks in both groups.

In conclusion, this pilot study showed that Entelon® reduced the RP attack frequency compared to nifedipine in patients with primary RP. In patients with intolerability of nifedipine, Entelon® may be an alternative therapeutic option. Further large-scale, long-term studies are needed to investigate the efficacy and safety of Entelon®.

**Ethics Committee Approval:** The trial was approved by the Institutional Review Board for Human Research (SCH 2016-08-023). The study was conducted in accordance with the principles of the Declaration of Helsinki.

**Patient Consent for Publication:** A written informed consent was obtained from each patient.

**Data Sharing Statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Author Contributions:** Analysis and/or interpretation, literature review, writing the article: K.A.L.; Data collection and/or processing: S.H.J.; Data collection and/or processing: J.S.K.; Idea/concept, design, control/supervision, references and funding: H.S.K.

**Conflict of Interest:** The authors declared no conflicts of interest with respect to the authorship and/or publication of this article. Hanlim Pharmaceutical Company had no role in the study design or in the

collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication. Publication of this article was not contingent upon approval by Hanlim Pharmaceutical Company.

**Funding:** This work was supported by the Soonchunhyang University Research Fund and Hanlim Pharmaceutical Company (Seoul, Korea).

## REFERENCES

1. Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. *Clin Rheumatol* 2019;38:3317-30.
2. Fine AM. Oligomeric proanthocyanidin complexes: History, structure, and phytopharmaceutical applications. *Altern Med Rev* 2000;5:144-51.
3. Zhu H, Li P, Ren S, Tan W, Fang G. Low-cost Ru/C-catalyzed depolymerization of the polymeric proanthocyanidin-rich fraction from bark to produce oligomeric proanthocyanidins with antioxidant activity. *ACS Omega* 2019;4:16471-80.
4. Moon SW, Shin YU, Cho H, Bae SH, Kim HK; and for the Mogen Study Group. Effect of grape seed proanthocyanidin extract on hard exudates in patients with non-proliferative diabetic retinopathy. *Medicine (Baltimore)* 2019;98:e15515.
5. Fardoun MM, Nassif J, Issa K, Baydoun E, Eid AH. Raynaud's phenomenon: A brief review of the underlying mechanisms. *Front Pharmacol* 2016;7:438.
6. Maverakis E, Patel F, Kronenberg DG, Chung L, Fiorentino D, Allanore Y, et al. International consensus criteria for the diagnosis of Raynaud's phenomenon. *J Autoimmun* 2014;48-49:60-5.
7. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. *Arthritis Rheum* 2002;46:2410-20.